temozolomide and Central Nervous System Neoplasm studies

Research Excerpts

Excerpt	Relevance	Reference
"The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival."	9.69	Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. ( Abe, K; Arakawa, Y; Asai, A; Asano, K; Fukuda, H; Gomyo, M; Katayama, H; Kinoshita, M; Koga, T; Kojima, M; Mishima, K; Mizusawa, J; Momii, Y; Nagane, M; Nakamura, S; Narita, Y; Natsumeda, M; Nishikawa, R; Sasaki, A; Sasaki, H; Sasaki, N; Sasayama, T; Shibahara, I; Shinojima, N; Sumi, M; Tamaru, JI; Tsuchiya, K; Tsurubuchi, T; Yamasaki, F; Yoshimoto, K, 2023)
"In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone."	9.24	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017)
"This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ."	9.22	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. ( Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M, 2016)
"To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse."	9.19	A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014)
"We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies."	9.17	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013)
"Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL)."	9.17	O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. ( Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ, 2013)
"In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx, PEG-Dox) and prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63 patients with newly diagnosed glioblastoma."	9.14	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. ( Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G, 2009)
"Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005."	9.14	Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. ( Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA, 2010)
"Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies."	8.98	Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018)
"Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma."	8.81	New approaches for temozolomide therapy: use in newly diagnosed glioma. ( Newlands, E; Stupp, R, 2001)
"Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance."	7.96	Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. ( Baek, ST; Hsieh, JT; Kim, S; Yun, EJ, 2020)
"Temozolomide, an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma."	7.80	miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. ( Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S, 2014)
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed."	7.80	Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014)
"The coumarins 5-methoxy-6,7-methylenedioxycoumarin 1 5-(3-methyl-2-butenyloxy)-6,7-methylenedioxycoumarin 2 and 5-(2,3-dihydroxy-3-methylbutyloxy)-6,7-methylenedioxycoumarin 3 isolated from Pterocaulon species showed significant cytotoxicity against two glioma cells lines."	7.78	Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. ( Battastini, AM; Bernardi, A; Eifler-Lima, VL; Figueiró, F; Hamerski, L; Pinto, AC; Pires, EN; Salbego, CG; Teixeira, HF; Vianna, DR; Visentin, LC; von Poser, GL, 2012)
"This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities."	7.76	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. ( Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M, 2010)
"We assessed the effect of AG-014699, a clinically active PARP inhibitor, on temozolomide-induced growth inhibition in human medulloblastoma models."	7.76	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. ( Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA, 2010)
"Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas."	7.74	Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007)
"The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients."	7.73	Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006)
"To analyze the effect of different therapies -surgery, radiotherapy, and chemotherapy (temozolomide)- on the survival of various groups of patients with glioblastoma multiforme (GBM)."	7.72	[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. ( Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P, 2004)
"We conducted a retrospective observational study that included patients with recurrent malignant glioma who where treated with temozolomide."	7.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only."	7.72	Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004)
"Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity."	6.82	Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016)
"Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile."	6.73	Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. ( Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L, 2007)
"Temozolomide (TMZ) is an oral alkylating agent with established effects on the central nervous system of glioblastoma (GBM) patients."	6.52	Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. ( Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW, 2015)
"radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched."	6.50	Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. ( Lin, ZX; Yang, LJ; Zhou, CF, 2014)
" For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits."	6.41	Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001)
"Temozolomide (TMZ) is a commonly used drug for GBM management."	5.72	Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. ( Chen, L; Deng, Q; Guo, S; Hao, P; Hu, S; Li, Z, 2022)
"The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival."	5.69	Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C. ( Abe, K; Arakawa, Y; Asai, A; Asano, K; Fukuda, H; Gomyo, M; Katayama, H; Kinoshita, M; Koga, T; Kojima, M; Mishima, K; Mizusawa, J; Momii, Y; Nagane, M; Nakamura, S; Narita, Y; Natsumeda, M; Nishikawa, R; Sasaki, A; Sasaki, H; Sasaki, N; Sasayama, T; Shibahara, I; Shinojima, N; Sumi, M; Tamaru, JI; Tsuchiya, K; Tsurubuchi, T; Yamasaki, F; Yoshimoto, K, 2023)
"Glioblastoma (GBM) is one of the lethal central nervous system tumors."	5.48	The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018)
"Glioblastoma is a deadly cancer with intrinsic chemoresistance."	5.38	Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. ( Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P, 2012)
"Glioblastoma multiforme is the most common and most malignant primary brain tumour."	5.36	Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010)
"In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone."	5.24	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017)
"This study investigated the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followed by hyperfractionated whole-brain radiotherapy (hWBRT) and subsequent TMZ."	5.22	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. ( Augspurger, M; Bartlett, NL; Bokstein, F; Bovi, JA; Brat, D; Fisher, BJ; Glass, J; Liepman, MK; Mehta, MP; Schultz, CJ; Solhjem, MC; Suh, JH; Werner-Wasik, M; Won, M, 2016)
"To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse."	5.19	A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014)
"Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL)."	5.17	O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. ( Austin, AD; Desjardins, A; Friedman, HS; Herndon, JE; Jiang, X; McLendon, RE; Quinn, JA; Reardon, DA; Vredenburgh, JJ, 2013)
"We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies."	5.17	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013)
"We evaluated a novel therapy for primary central nervous system lymphoma (PCNSL) with induction immunochemotherapy with high-dose methotrexate, temozolomide, and rituximab (MT-R) followed by intensive consolidation with infusional etoposide and high-dose cytarabine (EA)."	5.16	Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. ( Behler, CM; Cha, S; Damon, LE; Hwang, J; Issa, S; McDermott, M; O'Brien, J; Rubenstein, JL; Shuman, MA; Treseler, P; Valles, F; Wieduwilt, MJ, 2012)
"In this phase-I/II trial, pegylated liposomal doxorubicin (Caelyx, PEG-Dox) and prolonged administration of Temozolomide in addition to radiotherapy was investigated in 63 patients with newly diagnosed glioblastoma."	5.14	RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. ( Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G, 2009)
"Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005."	5.14	Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. ( Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA, 2010)
"Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy."	5.12	Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007)
"Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies."	4.98	Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018)
"Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma."	4.86	Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010)
"Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma."	4.81	New approaches for temozolomide therapy: use in newly diagnosed glioma. ( Newlands, E; Stupp, R, 2001)
" Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy."	4.81	Chemotherapy for the treatment of oligodendroglial tumors. ( Chinot, O, 2001)
" Preclinical and phase I trials have shown the additive or synergistic activity of temozolomide combined with carmustine against solid tumors, including malignant glioma, and the sequence-dependent effects of the combination."	4.81	Temozolomide in combination with other cytotoxic agents. ( Prados, M, 2001)
"Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance."	3.96	Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. ( Baek, ST; Hsieh, JT; Kim, S; Yun, EJ, 2020)
"In 2011, we reported a predominant prognostic/predictive role of MGMT promoter methylation status on progression-free survival (PFS) in unresectable glioblastoma patients undergoing upfront radiotherapy plus concomitant and maintenance temozolomide (RTX/TMZ → TMZ)."	3.85	Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. ( Belka, C; Eigenbrod, S; Kreth, FW; Kreth, S; Lutz, J; Niyazi, M; Schüller, U; Thon, N; Thorsteinsdottir, J; Tonn, JC, 2017)
"Temozolomide, an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma."	3.80	miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. ( Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S, 2014)
"As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed."	3.80	Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014)
"Radiochemotherapy, including > or = 6 cycles of adjuvant temozolomide, was safe and prolonged survival of glioblastoma patients aged > or = 60 years."	3.79	Post-operative management of primary glioblastoma multiforme in patients over 60 years of age. ( Bakó, G; Barzó, P; Bognár, L; Daróczi, B; Hideghéty, K; Mózes, P; Szántó, E; Szántó, J; Tóth, J, 2013)
"The coumarins 5-methoxy-6,7-methylenedioxycoumarin 1 5-(3-methyl-2-butenyloxy)-6,7-methylenedioxycoumarin 2 and 5-(2,3-dihydroxy-3-methylbutyloxy)-6,7-methylenedioxycoumarin 3 isolated from Pterocaulon species showed significant cytotoxicity against two glioma cells lines."	3.78	Selective cytotoxicity and apoptosis induction in glioma cell lines by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon species. ( Battastini, AM; Bernardi, A; Eifler-Lima, VL; Figueiró, F; Hamerski, L; Pinto, AC; Pires, EN; Salbego, CG; Teixeira, HF; Vianna, DR; Visentin, LC; von Poser, GL, 2012)
" There was particular interest in RTOG 0525, a Phase III study of newly diagnosed glioblastoma treated with different schedules of temozolomide."	3.77	American Society of Clinical Oncology 2011 CNS tumors update. ( Ahluwalia, MS, 2011)
"Early assessment of radiotherapy (RT) quality in the ongoing EORTC trial comparing primary temozolomide versus RT in low-grade gliomas."	3.76	Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. ( Aird, E; Bar-Deroma, R; Baumert, BG; Bernard Davis, J; Collette, L; Fenton, P; Gulyban, A; Musat, E; Roelofs, E; Stupp, R; Weber, DC, 2010)
"We assessed the effect of AG-014699, a clinically active PARP inhibitor, on temozolomide-induced growth inhibition in human medulloblastoma models."	3.76	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. ( Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA, 2010)
"This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities."	3.76	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. ( Glas, M; Herrlinger, U; Kurzwelly, D; Lohner, H; Reifenberger, G; Roth, P; Schabet, M; Waha, A; Weimann, E; Weller, M, 2010)
"Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas."	3.74	Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007)
"The authors investigated the safety of 75 mg/m2 temozolomide for 21 days every 28 days in glioma patients."	3.73	Is protracted low-dose temozolomide feasible in glioma patients? ( Blatt, V; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Pasetto, L; Scopece, L; Tosoni, A, 2006)
"Seven patients who had received rituximab and temozolomide were identified from the database of the brain tumor clinic at the authors' institution: three patients had developed recurrent primary CNS lymphoma (PCNSL), one patient had newly diagnosed PCNSL but had poor renal function, and three other patients with systemic non-Hodgkin lymphoma developed recurrent lymphoma in the brain only."	3.72	Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. ( Barron, L; Tishler, R; Wong, ET; Wu, JK, 2004)
"We conducted a retrospective observational study that included patients with recurrent malignant glioma who where treated with temozolomide."	3.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"To analyze the effect of different therapies -surgery, radiotherapy, and chemotherapy (temozolomide)- on the survival of various groups of patients with glioblastoma multiforme (GBM)."	3.72	[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. ( Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P, 2004)
"Metformin shows preclinical anti-cancer activity through multiple pathways."	3.30	A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation. ( Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA, 2023)
"Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity."	2.82	Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016)
"Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0."	2.75	Evaluation of the exposure equivalence of oral versus intravenous temozolomide. ( Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y, 2010)
"Temozolomide has emerged as a new alternative treatment for PCNSL and constitutes an attractive option for the elderly because of its favorable toxicity profile."	2.73	Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. ( Barrie, M; Carnin, C; Chinot, O; Hoang-Xuan, K; Omuro, AM; Taillandier, L, 2007)
"Gliomas are the most common central nervous system tumors."	2.72	Prognostic and Predictive Biomarkers in Gliomas. ( Bebyn, MG; Furtak, J; Kowalewski, J; Lewandowska, MA; Śledzińska, P, 2021)
"Using data derived from our population analysis, the sampling times for a limited sample pharmacokinetic model for temozolomide and MTIC in children are prior to the temozolomide dose, and 15 min, 1."	2.71	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. ( Freeman, BB; Gajjar, A; Iacono, LC; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF, 2005)
"Temozolomide has been available to oncologists for over 30 years."	2.58	Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System. ( Grossman, SA; Schreck, KC, 2018)
"Temozolomide (TMZ) is an oral alkylating agent with established effects on the central nervous system of glioblastoma (GBM) patients."	2.52	Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. ( Du, S; Liao, G; Ren, C; Sun, H; Xie, X; Yuan, YW, 2015)
"radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched."	2.50	Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. ( Lin, ZX; Yang, LJ; Zhou, CF, 2014)
"Temozolomide is a second-generation alkylating chemotherapeutic agent, introduced to therapy of primary brain tumors in the 1990s."	2.46	Temozolomide: Expanding its role in brain cancer. ( Adair, J; Kiem, HP; Mrugala, MM, 2010)
"Temozolomide has activity and a favorable safety profile in all dosing schedules tested."	2.42	Temozolomide: realizing the promise and potential. ( Dolan, ME; Nagasubramanian, R, 2003)
" For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits."	2.41	Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001)
"Temozolomide has the potential to be a useful agent in the treatment of a variety of cancers."	2.41	Future directions for temozolomide therapy. ( Yung, WK, 2001)
"The standard treatment for glioblastoma is 6 weeks of radiation therapy and daily temozolomide."	1.91	Safe administration of temozolomide in end-stage renal disease patients. ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023)
"Temozolomide (TMZ) is a commonly used drug for GBM management."	1.72	Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. ( Chen, L; Deng, Q; Guo, S; Hao, P; Hu, S; Li, Z, 2022)
"Temozolomide-induced aplastic anemia (TIAA) is a rare but highly challenging complication of temozolomide (TMZ) therapy."	1.72	Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. ( Al-Samkari, H; Forst, DA; Park, AK; Waheed, A, 2022)
"Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile."	1.51	Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019)
"Glioblastoma (GBM) is one of the lethal central nervous system tumors."	1.48	The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018)
"Temozolomide has recently emerged as an alternative option for PCNSL treatment."	1.40	MGMT promoter methylation and correlation with protein expression in primary central nervous system lymphoma. ( Canal, F; Cavallin, S; Dei Tos, AP; Gherlinzoni, F; Scarpa, M; Scquizzato, E; Stefani, PM; Toffolatti, L, 2014)
"Extensive work-up revealed lymphomatoid granulomatosis (LYG) with primary clinical manifestation in the central nervous system (CNS), a rare Epstein-Barr virus-driven multisystem lymphoproliferative disorder, to be causative for the symptoms."	1.40	Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman. ( Agaimy, A; Kloska, S; Linker, RA; Olmes, DG, 2014)
"Glioblastoma multiforme is the most common aggressive adult primary tumour of the central nervous system."	1.38	Temozolomide: mechanisms of action, repair and resistance. ( Bradshaw, TD; Stevens, MF; Zhang, J, 2012)
"Glioblastoma is a deadly cancer with intrinsic chemoresistance."	1.38	Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. ( Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P, 2012)
"Glioblastoma is the most common primary brain tumor with a dismal prognosis, highlighting the need for novel treatment strategies."	1.37	Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. ( Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S, 2011)
"Glioblastoma multiforme is the most common and most malignant primary brain tumour."	1.36	Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010)
" Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml)."	1.33	Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ( Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J, 2005)
"Temozolomide (TZM) is a DNA-methylating agent that has recently been introduced into various clinical trials for treatment of solid or hematologic neoplasias, including brain lymphomas."	1.31	Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. ( Bonmassar, E; d'Amati, G; Graziani, G; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Zupi, G, 2002)
" Pretreatment of mice with O6-benzylguanine increased temozolomide-induced mortality, requiring reduction of the dosage from 1200 to 750 mg/m2 on the single-day regimen."	1.29	Activity of temozolomide in the treatment of central nervous system tumor xenografts. ( Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC, 1995)

Research

Studies (131)

Authors

Clinical Trials (18)

Trial Overview

Trial Outcomes

Number of Phase I Participants Experiencing Toxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.76)	18.2507
2000's	43 (32.82)	29.6817
2010's	67 (51.15)	24.3611
2020's	20 (15.27)	2.80

Authors	Studies
Vianna, DR	1
Hamerski, L	1
Figueiró, F	1
Bernardi, A	1
Visentin, LC	1
Pires, EN	1
Teixeira, HF	1
Salbego, CG	1
Eifler-Lima, VL	1
Battastini, AM	1
von Poser, GL	1
Pinto, AC	1
Śledzińska, P	1
Bebyn, MG	1
Furtak, J	1
Kowalewski, J	1
Lewandowska, MA	1
Park, AK	1
Waheed, A	1
Forst, DA	1
Al-Samkari, H	1
Ashfaque, A	1
Hanif, F	1
Simjee, SU	1
Bari, MF	1
Faizi, S	1
Zehra, S	1
Mirza, T	1
Begum, S	1
Khan, L	1
Chen, L	3
Li, Z	1
Hu, S	1
Deng, Q	1
Hao, P	1
Guo, S	1
Zhai, Y	1
Shang, J	1
Yao, W	1
Wu, D	1
Fu, C	1
Yan, L	1
Metts, JL	1
Trucco, M	1
Weiser, DA	1
Thompson, P	1
Sandler, E	1
Smith, T	1
Crimella, J	1
Sansil, S	1
Thapa, R	1
Fridley, BL	1
Llosa, N	1
Badgett, T	1
Gorlick, R	1
Reed, D	1
Gill, J	1
Kaulen, LD	1
Baehring, JM	1
Mishima, K	2
Nishikawa, R	3
Narita, Y	2
Mizusawa, J	1
Sumi, M	1
Koga, T	1
Sasaki, N	1
Kinoshita, M	1
Nagane, M	2
Arakawa, Y	1
Yoshimoto, K	1
Shibahara, I	1
Shinojima, N	1
Asano, K	1
Tsurubuchi, T	1
Sasaki, H	1
Asai, A	1
Sasayama, T	1
Momii, Y	1
Sasaki, A	2
Nakamura, S	1
Kojima, M	1
Tamaru, JI	1
Tsuchiya, K	1
Gomyo, M	1
Abe, K	1
Natsumeda, M	1
Yamasaki, F	1
Katayama, H	1
Fukuda, H	1
Hundal, J	3
Singh, A	3
Pereira, MK	3
Vredenburg, J	3
David, KA	1
Sundaram, S	1
Kim, SH	1
Vaca, R	1
Lin, Y	1
Singer, S	1
Malecek, MK	1
Carter, J	1
Zayac, A	1
Kim, MS	1
Reddy, N	1
Ney, D	1
Habib, A	1
Strouse, C	1
Graber, J	1
Bachanova, V	1
Salman, S	1
Vendiola, JA	1
Hossain, N	1
Tsang, M	1
Major, A	1
Bond, DA	1
Agrawal, P	1
Mier-Hicks, A	1
Torka, P	1
Rajakumar, P	1
Venugopal, P	1
Berg, S	1
Glantz, M	1
Goldlust, SA	1
Folstad, M	1
Kumar, P	1
Ollila, TA	1
Cai, J	1
Spurgeon, S	1
Sieg, A	1
Cleveland, J	1
Chang, J	1
Epperla, N	1
Karmali, R	1
Naik, S	1
Martin, P	1
Smith, SM	1
Rubenstein, J	1
Kahl, B	1
Evens, AM	1
Feng, SW	1
Wu, ZS	1
Chiu, YL	1
Huang, SM	1
Yang, D	1
Cheng, X	1
Bu, X	1
Yan, Z	1
Wu, T	1
Zhang, Y	2
Wang, L	3
Li, X	2
He, YZ	1
Richard, S	1
Tachon, G	1
Milin, S	1
Wager, M	1
Karayan-Tapon, L	1
Yun, EJ	1
Kim, S	1
Hsieh, JT	1
Baek, ST	1
Yip, PL	1
Lam, CP	1
Lau, WP	1
Luk, TH	1
Lau, SJ	1
Li, C	1
Feng, S	1
Yalamanchi, M	1
Sharma, A	1
Nguyen, M	1
Truong, J	1
Carrillo, JA	1
Wagle, N	1
Gill, JM	1
Kesari, S	1
Renaud, L	1
Bossard, JB	1
Carpentier, B	1
Terriou, L	1
Cambier, N	1
Chanteau, G	1
Escure, G	1
Tilmont, R	1
Barbieux, S	1
Wemeau, M	1
Hieulle, J	1
Boyle, EM	1
Morschhauser, F	1
Daniele, S	1
Pietrobono, D	1
Costa, B	1
Giustiniano, M	1
La Pietra, V	1
Giacomelli, C	1
La Regina, G	1
Silvestri, R	1
Taliani, S	1
Trincavelli, ML	1
Da Settimo, F	1
Novellino, E	1
Martini, C	1
Marinelli, L	1
DeFilipp, Z	1
Li, S	2
El-Jawahri, A	1
Armand, P	1
Nayak, L	2
Wang, N	1
Batchelor, TT	1
Chen, YB	1
Abbassi, M	1
Riley, R	1
Malkin, M	1
Tang, Y	1
Rajendran, B	1
Yazbeck, V	1
Wang, H	2
Wang, M	1
Wei, J	1
Mao, L	1
Jin, J	1
Choi, DK	1
Pillay-Smiley, N	1
Marzec, S	1
Wadhwani, NR	1
DiPatri, AJ	1
Tomita, T	1
Lulla, RR	1
Grek, CL	1
Sheng, Z	1
Naus, CC	1
Sin, WC	1
Gourdie, RG	1
Ghatnekar, GG	1
Lukács, G	1
Tóth, Z	1
Sipos, D	1
Csima, M	1
Hadjiev, J	1
Bajzik, G	1
Cselik, Z	1
Semjén, D	1
Repa, I	1
Kovács, Á	1
Zheng, J	1
Wang, C	1
Liu, F	1
Ren, S	1
Xu, Y	1
Miao, W	1
Huang, X	1
Qu, Z	1
Li, J	1
Liu, X	1
Kong, P	1
Schreck, KC	1
Grossman, SA	1
Di Stefano, AL	1
Savatovsky, J	1
Feuvret, L	2
Villa, C	1
Reina, V	1
Pha, M	1
Houillier, C	3
Berzero, G	1
Idbaih, A	1
Psimaras, D	1
Sa, JK	1
Choi, SW	1
Zhao, J	1
Lee, Y	1
Zhang, J	4
Kong, DS	1
Choi, JW	1
Seol, HJ	1
Lee, JI	1
Iavarone, A	1
Rabadan, R	1
Nam, DH	1
Xu, X	1
Chen, K	1
Wu, H	1
Wang, Y	2
Yang, S	1
Wang, K	1
Chen, C	1
Sun, P	1
Cui, J	1
Yan, S	1
Chen, H	1
Xia, Y	1
Bi, X	1
Liu, P	1
Yang, H	1
Nie, M	1
Zhang, XW	1
Jiang, W	1
Li, ZM	1
Faivre, G	1
Butler, MJ	1
Le, I	1
Brenner, A	1
Ciammella, P	1
Galeandro, M	1
D'Abbiero, N	1
Podgornii, A	1
Pisanello, A	1
Botti, A	1
Cagni, E	1
Iori, M	1
Iotti, C	1
Jiang, X	1
Reardon, DA	4
Desjardins, A	1
Vredenburgh, JJ	1
Quinn, JA	1
Austin, AD	1
Herndon, JE	1
McLendon, RE	1
Friedman, HS	4
Shi, L	1
Wan, Y	1
Sun, G	1
Zhang, S	1
Wang, Z	1
Zeng, Y	1
Salamoon, M	1
Hussein, T	1
Kenj, M	1
Bachour, M	1
Reynés, G	2
Balañá, C	2
Gallego, O	2
Iglesias, L	1
Pérez, P	1
García, JL	1
Yang, LJ	1
Zhou, CF	1
Lin, ZX	1
Karpel-Massler, G	1
Westhoff, MA	1
Kast, RE	1
Dwucet, A	1
Nonnenmacher, L	1
Wirtz, CR	1
Debatin, KM	2
Halatsch, ME	1
Daróczi, B	1
Szántó, E	1
Tóth, J	1
Barzó, P	1
Bognár, L	1
Bakó, G	1
Szántó, J	1
Mózes, P	1
Hideghéty, K	1
Wang, XX	1
Huang, HQ	1
Bai, B	1
Cai, QQ	1
Cai, QC	1
Gao, Y	1
Xia, YF	1
Xia, ZJ	1
Jiang, WQ	1
Fuentes-Raspall, R	1
Puig-Vives, M	1
Guerra-Prio, S	1
Perez-Bueno, F	1
Marcos-Gragera, R	1
Toffolatti, L	1
Scquizzato, E	1
Cavallin, S	1
Canal, F	1
Scarpa, M	1
Stefani, PM	1
Gherlinzoni, F	1
Dei Tos, AP	1
Pulczynski, EJ	1
Kuittinen, O	1
Erlanson, M	1
Hagberg, H	1
Fosså, A	1
Eriksson, M	1
Nordstrøm, M	1
Østenstad, B	1
Fluge, Ø	1
Leppä, S	1
Fiirgaard, B	1
Bersvendsen, H	1
Fagerli, UM	1
Olmes, DG	1
Agaimy, A	1
Kloska, S	1
Linker, RA	1
Sun, H	1
Du, S	1
Liao, G	1
Xie, X	1
Ren, C	1
Yuan, YW	1
Omuro, A	3
Chinot, O	4
Taillandier, L	2
Ghesquieres, H	1
Soussain, C	2
Delwail, V	1
Lamy, T	1
Gressin, R	1
Choquet, S	2
Soubeyran, P	1
Huchet, A	1
Benouaich-Amiel, A	1
Lebouvier-Sadot, S	1
Gyan, E	1
Touitou, V	2
Barrié, M	2
del Rio, MS	1
Gonzalez-Aguilar, A	1
Delgadillo, D	1
Lacomblez, L	1
Tanguy, ML	1
Hoang-Xuan, K	3
Khasraw, M	1
Lee, A	1
McCowatt, S	1
Kerestes, Z	1
Buyse, ME	1
Back, M	2
Kichenadasse, G	1
Ackland, S	1
Wheeler, H	1
Glass, J	1
Won, M	1
Schultz, CJ	1
Brat, D	1
Bartlett, NL	1
Suh, JH	1
Werner-Wasik, M	2
Fisher, BJ	1
Liepman, MK	1
Augspurger, M	1
Bokstein, F	1
Bovi, JA	1
Solhjem, MC	1
Mehta, MP	1
Nguyen, DT	1
Cassoux, N	1
Le Cossec, C	1
Legarf-Tavernier, M	1
Costopoulos, M	1
LeHoang, P	1
Bodaghi, B	1
Li, ZY	1
Li, QZ	1
Chen, BD	1
Wang, B	1
Zhang, XJ	1
Li, WP	1
Hertenstein, A	1
Platten, M	2
Wick, W	2
Thon, N	1
Thorsteinsdottir, J	1
Eigenbrod, S	1
Schüller, U	1
Lutz, J	1
Kreth, S	1
Belka, C	1
Tonn, JC	1
Niyazi, M	1
Kreth, FW	1
Gokturk, D	1
Kelebek, H	1
Ceylan, S	1
Yilmaz, DM	1
Perry, JR	1
Laperriere, N	1
O'Callaghan, CJ	1
Brandes, AA	4
Menten, J	1
Phillips, C	1
Fay, M	1
Cairncross, JG	1
Roa, W	1
Osoba, D	1
Rossiter, JP	1
Sahgal, A	1
Hirte, H	1
Laigle-Donadey, F	1
Franceschi, E	2
Golfinopoulos, V	1
Fariselli, L	1
Wick, A	1
Tills, M	1
Winch, C	1
Baumert, BG	3
Ding, K	1
Mason, WP	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Safety of Intensity-modulated Radiotherapy Treatment With Inhomogeneous Dose Distribution in Patients With Relapsed High-grade Gliomas.[NCT04610229]		12 participants (Actual)	Interventional	2016-02-01	Completed
Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomi[NCT01458730]	Phase 2	66 participants (Actual)	Interventional	2007-05-31	Completed
Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly[NCT00503594]	Phase 2	92 participants (Anticipated)	Interventional	2007-07-31	Recruiting
A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655]	Phase 2	51 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma[NCT00068250]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2003-07-31	Completed
A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677]	Phase 3	562 participants (Actual)	Interventional	2007-11-14	Completed
Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma[NCT05653622]	Phase 2	75 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366]	Phase 2	21 participants (Actual)	Interventional	2016-02-29	Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients)
RNOP-09: Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma - a Phase II Study[NCT00944801]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2002-07-31	Completed
Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)[NCT01735747]	Phase 2	16 participants (Anticipated)	Interventional	2008-06-30	Active, not recruiting
Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study[NCT00182819]	Phase 3	709 participants (Actual)	Interventional	2005-07-31	Completed
Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas[NCT00575887]	Phase 2	25 participants (Actual)	Interventional	2006-08-31	Completed
Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: A Pilot Study[NCT00416819]		10 participants (Actual)	Interventional	2003-09-30	Completed
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma[NCT00248534]	Phase 2	16 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to slow accrual/lack of resources/low priority due to combining 2 consortia)
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795]	Phase 2	170 participants (Actual)	Interventional	2002-12-31	Completed
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2012-06-30	Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.)
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2013-10-22	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

A dose limiting toxicity (DLT) is defined as any grade 3 or 4 non-hematological toxicity (other than grade 3 nausea/vomiting) or any hematological toxicity resulting in the discontinuation of temozolomide. Toxicity evaluation for this dose escalation includes all toxicities occurring prior to the start of radiation therapy. If the patient did not receive radiation therapy, then toxicity evaluation included all toxicities occurring through week 15. Any grade 5 toxicity would result in immediate suspension of accrual. (NCT00068250)
Timeframe: From start of treatment to 10 weeks if radiation therapy received, to 15 weeks if not.

Phase II: Overall Survival Rate at 2 Years (Including Phase I Patients at Same Dose)

Intervention	Participants (Count of Participants)
Phase I: Temozolomide 100mg	1
Phase I: Temozolomide150 mg	3

Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (Please note that this outcome measure is considered the primary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.

Phase II: Progression-free Survival (Including Phase I Patients at Same Dose)

Intervention	percentage of participants (Number)
Combined Temozolomide 100mg Arms	80.8

Progression is defined as greater than 25% increase in enhancing tumor or the appearance of new lesions in the brain, eye, or the appearance of a new positive cerebrospinal fluid (CSF) cytology. The patient may be neurologically stable or worse and on stable or increasing doses of corticosteroid. Progression-free survival time is defined as time from registration to the date of progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. (Please note that this outcome measure is considered a secondary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: Analysis occured after all patients have been on study for 2 years. Maximum follow-up at time of analysis was 8.5 years.

Phase II: Pre-irradiation Chemotherapy Tumor Response Rate (Including Phase I Patients at Same Dose)

Intervention	years (Median)
Combined Temozolomide 100mg Arms	5.4

Tumor response was centrally reviewed. Complete response: Disappearance of all enhancing tumor, the patient must be off steroid therapy and neurologically stable or improved; partial response: ≥ 50% decrease in enhancing tumor; progressive disease: ≥ 25% increase in a lesion, progressive or newly emergent meningeal or ocular disease. (Please note that this outcome measure is considered a secondary endpoint for the Phase II component of the study, but that the patients from Phase I that were treated at the same dose level are included, as indicated in the treatment arm descriptions. ) (NCT00068250)
Timeframe: From start of treatment to 10 weeks if RT received, to 15 weeks if not.

Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter

Intervention	Participants (Count of Participants)
	Complete Response	Partial Response	Progressive Disease	Not evaluable
Combined Temozolomide 100mg Arms	18	12	2	3

Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years

Overall Survival

Intervention	Months (Median)
Temozolomide	13.47
Radiation	7.69

Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years

Progression-free Survival

Intervention	Months (Median)
Temozolomide	9.33
Radiation	7.62

Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years

Progression-free Survival at 6-months

1 Year Overall Survival Rate

6-month Progression-free Survival

Intervention	Months (Median)
Temozolomide	5.29
Radiation	3.94

Intervention	percentage of participants (Number)
Temozolomide	17.3

Intervention	percentage of participants (Number)
IV Rituximab	71

"Scan at 6 months~Complete response: Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks~Partial response: Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.~Progressive disease: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.~Stable disease: Clinical status and MRI does not qualify for complete response, partial response or progression" (NCT00248534)
Timeframe: 6 months

Number of Participants Alive at 3 Years

Intervention	percentage of participants (Number)
IV Rituximab	13

The intent was to measure Median Overall Survival at 3 years, however only one participant was analyzable at this time point. Therefore, the number of participants who survived is reported instead. (NCT00248534)
Timeframe: 3 years

Percentage of Participants With Objective Response

Intervention	Participants (Count of Participants)
IV Rituximab	1

Objective response rate of the combination of Rituximab and TMZ (NCT00248534)
Timeframe: 2 months

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	percent of participants (Number)
IV Rituximab	14

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

temozolomide and Central Nervous System Neoplasm